Evidence map›Paper›PMID 20607625›Full record

ArticleMolecular biotechnology2011

Vector insert-targeted integrative antisense expression system for plasmid stabilization.

Jeremy M Luke, Aaron E Carnes, Clague P Hodgson, James A Williams

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biotechnology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jeremy M LukeNature Technology Corporation, 4701 Innovation Drive, Lincoln, NE 68521, USA.
Aaron E Carnes
Clague P Hodgson
James A Williams
Nature Technology Corporation (United States) · US

Funding

Chimeric enzyme for nucleic acid autohydrolysisR44GM072141 · NIGMS · NATURE TECHNOLOGY CORPORATION · PI WILLIAMS, JAMES · 2006 to 2007
$910k
Antisense inhibitors for enhanced plasmid productionR43GM073394 · NIGMS · NATURE TECHNOLOGY CORPORATION · PI WILLIAMS, JAMES · 2005 to 2005
$136k
NIGMS NIH HHS R43GM073394NIGMS NIH HHS R44GM072141
6 · The paper itself

Abstract

Some DNA vaccine and gene therapy vector-encoded transgenes are toxic to the E. coli plasmid production host resulting in poor production yields. For plasmid products undergoing clinical evaluation, sequence modification to eliminate toxicity is undesirable because an altered vector is a new chemical entity. We hypothesized that: (1) insert-encoded toxicity is mediated by unintended expression of a toxic insert-encoded protein from spurious bacterial promoters; and (2) that toxicity could be eliminated with antisense RNA-mediated translation inhibition. We developed the pINT PR PL vector, a chromosomally integrable RNA expression vector, and utilized it to express insert-complementary (anti-insert) RNA from a single defined site in the bacterial chromosome. Anti-insert RNA eliminated leaky fluorescent protein expression from a target plasmid. A toxic retroviral gag pol helper plasmid produced in a gag pol anti-insert strain had fourfold improved plasmid fermentation yields. Plasmid fermentation yields were also fourfold improved when a DNA vaccine plasmid containing a toxic Influenza serotype H1 hemagglutinin transgene was grown in an H1 sense strand anti-insert production strain, suggesting that in this case toxicity was mediated by an antisense alternative reading frame-encoded peptide. This anti-insert chromosomal RNA expression technology is a general approach to improve production yields with plasmid-based vectors that encode toxic transgenes, or toxic alternative frame peptides.

Indexed as

Gene Expression Regulation, BacterialGenetic VectorsEscherichia coliFusion Proteins, gag-polPlasmidsRetroviridaeRNA, AntisenseTransgenesFusion Proteins, gag-polRNA, Antisense

Identifiers

PMID20607625
OpenAlexW1976173386

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.